A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 28 Nov 2017 Planned End Date changed from 24 Jan 2018 to 31 Jan 2018.
- 01 Nov 2017 Planned End Date changed from 1 Feb 2018 to 24 Jan 2018.
- 18 Oct 2017 Planned End Date changed from 17 Jul 2018 to 1 Feb 2018.